$116.02
Live
Novartis AG is a multinational pharmaceutical company that produces and markets innovative medicines, eye care products, and generics.
0.11%
Downside
Day's Volatility :0.82%
Upside
0.71%
20.54%
Downside
52 Weeks Volatility :23.76%
Upside
4.05%
Period | Novartis Ag | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 7.77% | 3.6% | 0.0% |
6 Months | 23.19% | 10.2% | 0.0% |
1 Year | 23.75% | 19.6% | 0.0% |
3 Years | 38.4% | 16.8% | -23.0% |
Market Capitalization | 236.0B |
Book Value | $20.61 |
Dividend Share | 3.919 |
Dividend Yield | 3.24% |
Earnings Per Share (EPS) | 4.88 |
PE Ratio | 23.88 |
PEG Ratio | 4.22 |
Wall Street Target Price | 117.9 |
Profit Margin | 33.11% |
Operating Margin TTM | 33.41% |
Return On Assets TTM | 8.86% |
Return On Equity TTM | 21.5% |
Revenue TTM | 48.9B |
Revenue Per Share TTM | 23.87 |
Quarterly Revenue Growth YOY | 9.6% |
Gross Profit TTM | 36.7B |
EBITDA | 19.3B |
Diluted Eps TTM | 4.88 |
Quarterly Earnings Growth YOY | 0.43 |
EPS Estimate Current Year | 7.54 |
EPS Estimate Next Year | 8.35 |
EPS Estimate Current Quarter | 1.89 |
EPS Estimate Next Quarter | 1.93 |
What analysts predicted
Upside of 1.62%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 53.2B | ↑ 6.05% |
Net Income | 12.6B | ↑ 63.72% |
Net Profit Margin | 23.72% | ↑ 8.36% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 48.7B | ↓ 8.44% |
Net Income | 7.1B | ↓ 43.33% |
Net Profit Margin | 14.68% | ↓ 9.04% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 49.9B | ↑ 2.51% |
Net Income | 8.1B | ↑ 12.94% |
Net Profit Margin | 16.18% | ↑ 1.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 52.9B | ↑ 5.97% |
Net Income | 24.0B | ↑ 197.58% |
Net Profit Margin | 45.43% | ↑ 29.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 51.8B | ↓ 1.98% |
Net Income | 7.0B | ↓ 71.05% |
Net Profit Margin | 13.42% | ↓ 32.01% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 46.7B | ↓ 9.97% |
Net Income | 14.9B | ↑ 113.52% |
Net Profit Margin | 31.83% | ↑ 18.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.2B | ↑ 0.92% |
Net Income | 2.3B | ↑ 56.41% |
Net Profit Margin | 17.36% | ↑ 6.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.9B | ↑ 5.51% |
Net Income | 2.3B | ↑ 1.0% |
Net Profit Margin | 16.62% | ↓ 0.74% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1B | ↓ 13.23% |
Net Income | 1.8B | ↓ 23.96% |
Net Profit Margin | 14.56% | ↓ 2.06% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.8B | ↓ 2.61% |
Net Income | 8.5B | ↑ 381.54% |
Net Profit Margin | 72.01% | ↑ 57.45% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.8B | ↑ 0.45% |
Net Income | 2.7B | ↓ 68.3% |
Net Profit Margin | 22.72% | ↓ 49.29% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.5B | ↑ 5.77% |
Net Income | 3.2B | ↑ 20.76% |
Net Profit Margin | 25.94% | ↑ 3.22% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 145.6B | ↑ 9.38% |
Total Liabilities | 66.9B | ↑ 13.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 118.4B | ↓ 18.68% |
Total Liabilities | 62.8B | ↓ 6.06% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 132.1B | ↑ 11.56% |
Total Liabilities | 75.4B | ↑ 20.02% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 131.8B | ↓ 0.2% |
Total Liabilities | 64.0B | ↓ 15.15% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 117.5B | ↓ 10.88% |
Total Liabilities | 58.0B | ↓ 9.29% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 99.9B | ↓ 14.91% |
Total Liabilities | 53.2B | ↓ 8.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 112.2B | ↓ 4.44% |
Total Liabilities | 60.1B | ↑ 3.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 111.0B | ↓ 1.12% |
Total Liabilities | 59.0B | ↓ 1.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 112.7B | ↑ 1.55% |
Total Liabilities | 74.5B | ↑ 26.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 99.9B | ↓ 11.32% |
Total Liabilities | 53.2B | ↓ 28.55% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 94.3B | ↓ 5.61% |
Total Liabilities | 54.6B | ↑ 2.6% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 97.5B | ↑ 3.36% |
Total Liabilities | 55.6B | ↑ 1.88% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.3B | ↑ 13.08% |
Investing Cash Flow | -5.6B | ↑ 79.26% |
Financing Cash Flow | -4.2B | ↓ 45.12% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.6B | ↓ 4.53% |
Investing Cash Flow | -2.2B | ↓ 60.19% |
Financing Cash Flow | -13.6B | ↑ 221.09% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.7B | ↑ 0.18% |
Investing Cash Flow | -13.2B | ↑ 492.18% |
Financing Cash Flow | -2.2B | ↓ 83.8% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.1B | ↑ 10.41% |
Investing Cash Flow | 4.2B | ↓ 131.92% |
Financing Cash Flow | -16.3B | ↑ 636.59% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.2B | ↓ 5.54% |
Investing Cash Flow | 1.5B | ↓ 65.11% |
Financing Cash Flow | -20.6B | ↑ 26.43% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.5B | ↑ 1.56% |
Investing Cash Flow | 5.6B | ↑ 281.2% |
Financing Cash Flow | -14.3B | ↓ 30.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0B | ↓ 28.07% |
Investing Cash Flow | 10.6B | ↑ 623.5% |
Financing Cash Flow | -9.2B | ↑ 130.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.6B | ↑ 20.93% |
Investing Cash Flow | -1.1B | ↓ 109.91% |
Financing Cash Flow | -3.6B | ↓ 60.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.4B | ↑ 50.39% |
Investing Cash Flow | -2.2B | ↑ 110.07% |
Financing Cash Flow | -832.0M | ↓ 77.12% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↓ 52.64% |
Investing Cash Flow | -1.8B | ↓ 20.43% |
Financing Cash Flow | -607.0M | ↓ 27.04% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↓ 11.07% |
Investing Cash Flow | -899.0M | ↓ 48.92% |
Financing Cash Flow | -5.2B | ↑ 750.74% |
Sell
Neutral
Buy
Novartis Ag is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Novartis Ag | 0.7% | 23.19% | 23.75% | 38.4% | 35.37% |
Eli Lilly And Company | -0.06% | 25.52% | 59.19% | 280.63% | 750.68% |
Johnson & Johnson | 1.16% | 10.73% | 9.07% | 1.05% | 28.98% |
Merck & Co. Inc. | -5.99% | -14.37% | 5.18% | 33.92% | 28.61% |
Abbvie Inc | -2.56% | 12.49% | 30.49% | 73.65% | 144.32% |
Amgen Inc. | -4.16% | 18.3% | 17.8% | 53.91% | 58.51% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Novartis Ag | 23.88 | 23.88 | 4.22 | 7.54 | 0.22 | 0.09 | 0.03 | 20.61 |
Eli Lilly And Company | 112.5 | 112.5 | 0.87 | 13.38 | 0.59 | 0.14 | 0.01 | 15.06 |
Johnson & Johnson | 27.19 | 27.19 | 0.96 | 9.93 | 0.22 | 0.08 | 0.03 | 29.72 |
Merck & Co. Inc. | 20.32 | 20.32 | 0.08 | 7.9 | 0.33 | 0.11 | 0.03 | 17.19 |
Abbvie Inc | 63.07 | 63.07 | 0.45 | 10.87 | 0.54 | 0.08 | 0.03 | 3.84 |
Amgen Inc. | 55.5 | 55.5 | 2.24 | 19.49 | 0.49 | 0.04 | 0.03 | 11.03 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Novartis Ag | Buy | $236.0B | 35.37% | 23.88 | 33.11% |
Eli Lilly And Company | Buy | $826.6B | 750.68% | 112.5 | 18.86% |
Johnson & Johnson | Buy | $395.9B | 28.98% | 27.19 | 16.74% |
Merck & Co. Inc. | Buy | $278.2B | 28.61% | 20.32 | 21.99% |
Abbvie Inc | Buy | $333.1B | 144.32% | 63.07 | 9.71% |
Amgen Inc. | Buy | $172.7B | 58.51% | 55.5 | 10.12% |
Insights on Novartis Ag
Revenue is up for the last 3 quarters, 11.77B → 12.51B (in $), with an average increase of 3.0% per quarter
Netprofit is up for the last 2 quarters, 2.68B → 3.24B (in $), with an average increase of 17.2% per quarter
In the last 1 year, Eli Lilly And Company has given 57.0% return, outperforming this stock by 33.2%
In the last 3 years, Eli Lilly And Company has given 280.6% return, outperforming this stock by 242.2%
Dodge & Cox
PRIMECAP Management Company
Morgan Stanley - Brokerage Accounts
Dimensional Fund Advisors, Inc.
Loomis, Sayles & Company LP
Franklin Resources Inc
In the quarter ending March,2024. Novartis Ag has declared dividend of $3.78
Read MoreNovartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Organization | Novartis Ag |
Employees | 76057 |
CEO | Dr. Vasant Narasimhan M.D. |
Industry | Health Technology |